Member Info for MIKODX

As expected, bags of potential but no actual sales or expectations of sales, apart from the UK Govt first order. I've been here since March so wouldn't class myself as a LT holder, but as someone who's been here for some time, from what I can see ODX turnover is around 10M max with net profit of around £3M, these are average max figures it's more likely less.

Going by these figures how much would you say Omega is really worth going by current income, and do you think they are under or overvalued.?

Take for example Sam_Pullcox. His name alone tells you he's a knob, but if you read his comments, you will see how much of a bigger knob he is, and he's definitely deramping.

Just click on the users profile. From their comments you will be able to work out whether they are derampers, or just genuinely and honestly informing investors of the facts. It's not rocket science.

I now see why there's been shorting going on, there's a gap on 26 August.

Post Period End 30th Sep 2020

· Acquired the CHIMagents team in July, reinforcing hVIVO's position as the world leading services company in the testing of vaccines and antivirals through human challenge study clinical trials.

· Integrated hVIVO's unparalleled database of infectious diseases progression data into the Open Orphan data platform - expecting potential commercialisation in Q4, with some of the world's largest wearable companies for this disease progression data.

· Progressing as planned to monetise two of our non-core assets, the 49% stake in Imutex and the 62.6% stake in PrEP.

· The Company continues to provide testing to large commercial employers in the UK and Ireland as part of a combined COVID-19 antibody and COVID-19 PCR (swab) testing offering.

· Contracts signed post period end include:
- Laboratory services contracts signed with a number of parties - a key strategic growth area for Open Orphan taking advantage of our laboratory expertise.

- Contract signed with Codagenix Inc. for a first-in-human Phase I COVID-19 vaccine study, demonstrating that hVIVO's quarantine facility is uniquely suited to conducting Phase I studies for infectious disease vaccines such as this.

- Further RSV human challenge study contract for £4m signed with a Top 3 global pharma company with hVIVO acting as sponsor for this study.

- First-in-human clinical pharmacology trial signed with Carna BioSciences.

- Contract signed with a major European pharmaceutical company for data management, statistics and medical writing to support a 750 subject oncology study.

- Contract signed for a further £4.3m human challenge study with a top 10 global vaccine company.

November:

- Open Orphan/hVIVO Signs Contract with UK Government for the Development of a COVID-19 Human Challenge Study Model

- New £2.5m Influenza Challenge Study Contract Win

- Collaboration with HIC-VAC and Wellcome Trust

- Post completion of Merger, reduction in overheads on target to deliver annualized cost efficiencies of GBP £10.1m by end of 2020

OO is in a very good place and will start moving up. Patience required.

No time stated but last year it was 07:00am.

Don't think this is Mologic.

It has been both a difficult and an exhilarating start to 2020. Whilst it is difficult to forecast what the future levels of revenue from the Longhorn products might be, the Board expects continued and strong overall growth from the business throughout 2020, particularly in the US.

So far, Q3 2020 trading performance is in line with management expectations, and remains significantly above our internal budget. We are seeing continued benefit due to the demand for PrimeStore MTM tubes and bulk liquid, including the recently awarded contract with a large UK customer and we are investigating and commencing supply of additional products.

Meanwhile we look forward to McKesson returning to pre-pandemic sales expectations, as well as business generally improving in the second half of 2020. As a result of these signs of improved performance in both Diabetes and Hematology, and the continued demand for PrimeStore MTM, we remain confident that, for the full year, we will exceed previously revised management expectations.

From a regulatory viewpoint, we expect to see the completion of Quo-Test cartridge registration in China which is expected before the end of Q1 2021, and negotiations are under way with potential distributors to sell both analysers and tests in 2021.

On 1 Dec, 1p per share.

Once that's out the way hopefully we can start climbing next month.

Orusur's key Investors are:

Newmont Mining Corporation 18.23%
Interactive Investor Trading 7.58%
Hargreaves Lansdown 6.53%
Loryser (Uruguay) 6.24%
Barclays Bank 5.76%
Continental Investment Partners 4.70%
Lloyds Banking Group 3.85%

If that's not confidence for you I don't know what is.

We are not due and RNS, we will most definitely be getting an RNS,
first thing in the morning most probably like last year..
It's also stated in the ODX Financial Diary.

I expect this turn around very soon which is why I've jumped on board.

GLAH.

Thanks Reckoner. I hate Short positions it normally throw s me. Problem is I know all about 4D and understand exactly what they have planned. The US market are very excited about the health benefits live biotheraputics brings especially to cancer patients. That along with IBS candidate Blautix there will be a huge market demand for these treatments. I'll probably just take the plunge with this one as a long term investment. I'll see how Monday pans out.

The big question is regarding the uk-rtc antibody tests. The deal was we would be churning out 200,000 tests pw in October, ramped up to 300,000 pw in November. We are now at the end of November and so far ODX has only received 250,000 tests. They have fallen well below the numbers that were projected.

This is no fault of Omega, the delays have come from the govt. It looks like they are now having a change of heart especially after the success in Liverpool. They are now pumping resources into ramping up rapid antigen testing and stepping up track and trace. Antibody testing seems to have taken a back seat.

I believe all is still well with the Govt deal, just that Omega will not be getting the numbers they forecasted. Once the second UK order comes in, the doors for selling abroad should open, and if Mologic can get approved then it's all systems go. But at the rate the company is moving, they are where they should be. With a Good RNS on Monday this should get moving, hopefully in the right direction.

Thinking of buying in, but that Short position is making me think twice.

Do you think it can be safely ignored?

Lovejoy22 - I prefer the S&S myself, zero to no chance with that one.

I hope I do. If it opens on Monday at a stupid price then I'll obviously pass. But even if I can get in the late 50's I'll take that. As long as you've done the maths and you think ODX has the potential of getting to 80, 90, or even £1 then you should be quids in. That would be much better than the money it would have earned sitting in the bank, a potential multibag.

But as always, there's always risk, especially with AIM. It's all about knowing when to get in, and knowing when to get out.

Very very low trade volume today. Looks like everyone is thinking just like me, wont be investing a penny more until I hear exactly what is happening on Monday. Hope it's good news especially for the LT holders who have watched good money slip through their fingers. Roll on Monday.

GLAH

Averaged down thankfully. Looks like we could be on the move, and very close to news on commencement of drilling.

Just topped up, that brings my average down nicely.

News on how Foralumab for Covid19 is doing in Brazil, or our pending transfer onto the main stock market will
round things off a treat. Look forward to next week.

GLAH